Cardiac Surgery With Cardiopulmonary BypassPhosphoIRANCT02900313
Serum Phosphatemia Predictive Marker for AKI Diagnosis After Cardiac Surgery
A study testing cardiac surgery in people with Cardiac Surgery With Cardiopulmonary Bypass and Complete Serum Phosphorus Measure, run by University Hospital, Montpellier at 1 site in France.
Trial summary
Cardiac surgery associated acute kidney injury is an independent factor of morbidity and mortality . Despite its delayed elevation, serum creatinine (Cr) remains the goal standard to diagnose AKI. Hyperphosphatemia is well-know in case of AKI because of its excretion decrease. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiac Surgery With Cardiopulmonary Bypass, Complete Serum Phosphorus Measure, Complete Serum Creatinine Measure
- What is being tested?
- cardiac surgery
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 264 participants
- Where
- 1 siteFrance
- Study dates
- Oct 2015to Jul 2016
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- All the patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
Who cannot join
- Chronic renal insufficiency with a glomerular filtration rate = 15ml / min / 1.73m2
- Chronic Renal insufficiency dialysed
- History of single kidney or nephrectomy
- Vulnerable people according to the article L1121-6 of the public health Code
- Protected adult or in the incapacity to give his consent according to the article L1121-8 of the public health Code
- The patient present formalizes his opposition for the continuation of the study
- Pregnant or breast-feeding Women according to the article L1121-5 of the Public health Code
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predictive Interest of Serum Phosphorus Level in the Early Diagnosis of Acute Renal Insufficiency in Post-operative Immediate at Patients Having Benefited From a Cardiac Surgery.
Cardiac surgery associated acute kidney injury is an independent factor of morbidity and mortality . Despite its delayed elevation, serum creatinine (Cr) remains the goal standard to diagnose AKI. Hyperphosphatemia is well-know in case of AKI because of its excretion decrease. Moreover, serum phosphorus (Ph) is daily measure d after cardiac surgery since its variation may lead to cardiac dysfunction. In case of AKI, Ph may reflect the decrease of renal function in this context. Consequently, the purpose of this study is to evaluate the predictibility of Ph to detect both AKI induction and in a second time, renal recovery.
Read the detailed description
It is a one-year prospective diagnostic validation study included all patients > 18 years-odl admitted in our center after cardiac surgery. AKI is define according to KDIGO criteria and classified in the groups of severity according to the Cr elevation and the need of renal replacement therapy. Serum Cr and Ph are measured at baseline before surgery , at ICU admission, every 12 hours until ICU discharge and every 24 hours until hospital discharge. To evaluate the predictability of Of Ph to diagnose AKI, the postoperative Ph percentage of maximal elevation (%EPh) will be calculated. Then the diagnostic performance of %EPh wil be assessed by calculating the areas under the Receiver Operating Characteristic Curve (AUC) to determine an optimal threshold with sensibility, specificity, positive predictive value and negative predictive value.
- Conditions
- Cardiac Surgery With Cardiopulmonary Bypass, Complete Serum Phosphorus Measure, Complete Serum Creatinine Measure
- Being tested
- cardiac surgery
- Keywords
- acute kidney injury, cardiac surgery, cardiac surgery associated acute kidney injury, renal replacement therapy, renal recovery, serum hyperphosphatemia
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cardiac surgeryOther
Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
| Study group | Role | What they receive |
|---|---|---|
| Patients having cardiac surgery | Other | Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation Receives: Other: cardiac surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dosage of phosphorus
Kinetic phosphorus during acute renal failure in postoperative cardiac surgery
Measured: 48 hour after cardiac surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2016 (estimated)
- Study startOct 2015
- Primary completionApr 2016
- Study completionJul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac Surgery With Cardiopulmonary BypassStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 264 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Marine SAOUR, MD, Principal investigator, University Hospital, Montpellier
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02900313
- Sponsor's protocol ID
- UF9585
- Other IDs
- 2015-A00781-48
- Acronym
- PhosphoIRA
- Status last verified
- Jun 2015
- First submitted
- 16 Aug 2016
- Last updated
- 3 Oct 2017
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided